System, Heart, and Other Peripheral Sites
I. Introduction
T HIS REVIEW DESCRIBES the enzymes involved in the biosynthesis of active steroid hormones from cholesterol in gonads, adrenal glands, and placenta, with emphasis on the human and mouse enzymes. Figure 1 illustrates all of the enzymes involved in the biosynthesis of the adrenal steroid hormones, corticosterone, cortisol, and aldosterone; and the gonadal steroid hormones, progesterone, estradiol, and testosterone. These enzymes fall into two major classes of proteins: the cytochrome P450 heme-containing proteins (Table 1 ) and the hydroxysteroid dehydrogenases ( Table 2) . Tables 1 and 2 list the human and mouse genes that encode the enzymes described in this review, the gene symbol for each, the chromosomal location of each gene, the nomenclature and synonyms found in the literature for the proteins, the molecular mass and major tissue sites of expression of each enzyme, as well as the nucleotide and protein accession numbers.
Significant advances have occurred in the genetics, biochemistry, and molecular biology of steroidogenic enzymes since the last comprehensive review in 1988 (1) . Major new developments include the cloning, identification, and characterization of multiple isoforms of 3␤-hydroxysteroid dehydrogenase (3␤HSD) in human (2, 3) , mouse (4 -7) , and rat (8) . These isoforms are highly homologous in their amino acid (aa) composition, but are all products of distinct genes and are expressed in a cell-and tissue-specific manner. Nine different isozymes of 17␤-hydroxysteroid dehydrogenase (17␤HSD) have been cloned from human tissue (9) . Unlike the 3␤HSDs, the 17␤HSDs show little aa homology. They differ in tissue-specific expression, catalytic activity, substrate-specificity, and subcellular localization. In 1991, it was discovered that distinct enzymes are involved in the adrenal biosynthesis of corticosterone and cortisol and the biosynthesis of aldosterone. Curnow et al. (10) identified a second isoform of CYP11B in human, CYP11B2, which was found to be the only enzyme that could catalyze both 11␤-hydroxylation and 18-hydroxylation and thus is essential for the biosynthesis of aldosterone. CYP11B1 does not have the capacity for 18-hydroxylation, as previously believed (10) . In the same year, Domalik et al. (11) demonstrated that the mouse genome also contains two highly homologous Cyp11b genes, Cyp11b1 and Cyp11b2. As with the products of the human gene, mouse CYP11B1 has the capacity for 11␤-hydroxylation and is responsible for the biosynthesis of corticosterone, whereas the product of the Cyp11b2 gene, CYP11B2, is required for the biosynthesis of aldosterone (11) . Additional advances include detailed studies of the CYP19 gene, which describe the unique manner that determines tissue-specific expression of CYP19 (P450aromatase) through utilization of alternative promoters (12) . More recently, as described in Section IV, evidence has been presented for the expression of steroidogenic enzymes in the nervous system (13, 14) and in the heart (15) (16) (17) .
An important discovery in the regulation of tissue-specific expression of gonadal and adrenal steroidogenic enzymes was reported in 1992 by two laboratories. These laboratories identified a transcription factor that is required for the tissue-specific expression of P450 steroidogenic enzymes as well as the gonadal and adrenal-specific isoform of 3␤-HSD in gonads and adrenal glands, but not in placenta (18) . This transcription factor, a member of the steroid hormone receptor superfamily, was named steroidogenic factor-1 (SF-1) by Lala et al. (19) and adrenal 4-binding protein (Ad4BP) by Morohashi et al. (20) . The role of SF-1 and the role of other factors involved in the regulation of expression of the steroidogenic enzymes in gonads, adrenal glands, and the placenta are discussed in the sections titled "Regulation of Expression" under each specific class of enzymes.
II. Cytochrome P450s
The recommended nomenclature for the cytochrome P450 genes is CYP for the human genes and Cyp for the mouse genes, followed by an Arabic number representing the P450 family and a letter indicating the subfamily (21) . When two or more subfamilies exist, the letter is followed by an Arabic number indicating the individual gene, e.g., CYP11A, CYP11B1, CYP11B2. The preferred nomenclature for the corresponding proteins is CYP11A, CYP11B1, and CYP11B2, respectively. For synonyms of the P450 steroidogenic enzymes, see Table 1 .
The P450 enzymes involved in steroid hormone biosynthesis are membrane-bound proteins associated with either the mitochondrial membranes CYP11A, CYP11B1, and CYP11B2, or the endoplasmic reticulum (microsomal) CYP17, CYP19, and CYP21. These P450 enzymes are members of a superfamily of heme-containing proteins found in bacteria, fungi, plants, and animals (21) . They derive their name from the characteristic that, when complexed in vitro with exogenous CO, they absorb light maximally at 450 nm. In the biosynthesis of steroid hormones from cholesterol, cytochrome P450 enzymes catalyze the hydroxylation and cleavage of the steroid substrate. They function as monooxygenases utilizing reduced nicotinamide adenine dinucleotide phosphate (NADPH) as the electron donor for the reduction of molecular oxygen. The general reaction is
In this reaction, the oxygen is activated by P450, and one oxygen atom is introduced into the substrate RH as a hydroxyl group, whereas the other atom of oxygen is reduced to H 2 O. The electrons from NADPH are transferred to the substrate by two distinct electron transfer systems. The mitochondrial transfer involves transfer of the high potential electron to a flavoprotein, adrenodoxin reductase (ferredoxin reductase); and then sequentially to adrenodoxin (ferredoxin), a nonheme iron-sulfur protein; to P450; and finally to the substrate (Fig. 2A) . The microsomal electron transfer system involves only one protein, cytochrome P450 oxidoreductase, a protein that contains two flavins. The electrons are transferred from NADPH to a flavinadenine dinucleotide, followed sequentially by transfer to flavinmononucleotide, P450, and the substrate (Fig. 2B) . A. CYP11A
1. Reaction catalyzed. CYP11A (P450scc) catalyzes the first and rate-limiting enzymatic step in the biosynthesis of all steroid hormones (Fig. 1) . The reaction requires three molecules of oxygen, three molecules of NADPH, and the mitochondrial electron transfer system described above. CYP11A catalyzes three sequential oxidation reactions of cholesterol with each reaction requiring one molecule of O 2 and one molecule of NADPH (Fig. 3) . The first reaction is hydroxylation at C22, followed by hydroxylation at C20 to yield 20,22R-hydroxycholesterol that is cleaved between C22 and C20 to yield the C21 steroid pregnenolone and isocaproaldehyde (22, 23) .
Isocaproaldehyde is then oxidized to isocaproic acid (24) . Studies on purified proteins as well as studies with recombinant proteins from CYP11A cDNAs have provided conclusive evidence that a single protein catalyzes all three reactions at a single active site (25, 26) . The electrons required for the reaction are transferred from NADPH to ferredoxin reductase, to ferredoxin, and finally to CYP11A (27) . A model of the interactions between CYP11A and the electron transport proteins has been proposed based on the expression of mutants. The results of these studies indicate that the acidic residues, Asp 74 and Asp 76, of ferredoxin interact with the basic residues of ferredoxin reductase and CYP11A (28).
2. Molecular structure. CYP11A is the product of a single gene. The cDNA was first isolated from bovine adrenal cortex mRNA in 1984 by Morohashi et al. (29) . To date, CYP11A cDNA has been cloned from human (30) , rat (31), mouse (32) , and numerous other species. The deduced aa sequence exhibits high homology among the species, equal to or greater than 71%. The open reading frame of human cDNA encodes peptides consisting of 521 aa (30, 33) . The 39 aa at the amino terminus comprises the N-terminal leader sequence essential for translocation of the protein to the inner mitochondrial membrane. When this leader sequence is removed, the mature human protein consists of 482 aa (29, 30, 33, 34) . The aa sequence contains a heme-binding region that is located close to the carboxyl terminus containing a single cysteine residue common to the P450 gene superfamily (29) , and a specific 20-aa region of high homology among species that is located at the amino terminus and is proposed to be the CYP11A-specific substrate-binding region (35) . The structure of the cholesterol side-chain cleavage gene, CYP11A (Table 1) , has been determined in human (33) and rat (36) . The gene is at least 20 kb and consists of nine exons containing an unusual exon/intron junctional sequence that begins with GC in the sixth intron of both human (33) and rat genes (36) 15q23-q24 (30) , and the mouse gene is found on chromosome 9 at 31 cM (37).
Tissue-and developmental-specific expression.
The major sites of expression of CYP11A are in the adrenal cortex, ovary, testis, and placenta. In addition, CYP11A has been detected in the central and peripheral nervous system (38) and in human and rodent heart (15, 16) . In the adrenal cortex, CYP11A is expressed in all three zones, the zona fasciculata, the zona reticularis, and the zona glomerulosa (39, 40) . In the ovary, CYP11A is expressed in the theca interna and the granulosa cells of ovulatory follicles, but not in small antral follicles (36) . The only site of expression in the testis is the Leydig cell (41) . In the primate placenta, the synciotrophoblast cell is the site of expression of CYP11A (42) , whereas in rodent placenta, CYP11A is expressed in giant trophoblast cells during midpregnancy (32, 43, 44) . Before the expression of CYP11A in giant trophoblast cells during midpregnancy, expression of the CYP11A protein was demonstrated in decidual mitochondria at embryonic day (E) 6.5 (32, 43, 44) . During embryogenesis, the earliest expression of CYP11A mRNA in mouse was observed at E10.5 in the urogenital ridge, with significant expression observed in fetal testis by E12.5 (45) . CYP11A mRNA expression in fetal testis continues throughout pregnancy with little if any expression observed in the fetal ovary (45, 46) . Studies on the expression of steroidogenic enzyme mRNA in human fetal adrenal glands and gonads between 12 and 26 wk found that CYP11A was most abundant in the adrenal gland between 20 and 21 wk, followed by testis, with only minor expression in fetal ovaries (47) . Testicular expression showed a decrease from a high at about 15 wk to significantly lower levels by 26 wk (47) . Postnatally, in both rodents (48) and humans (49) , testicular expression of CYP11A decreases due to the disappearance of the fetal Leydig cell population. As development of the adult population of Leydig cells occurs [in rodents after postnatal day 10 (48, 50) and in humans at the beginning of pubertal development (49) ], there is a sharp increase in the expression of CYP11A reaching adult levels in mouse by postnatal day 25 (50) . In mouse adrenal primordium, CYP11A expression was observed as early as E11 (45) and in rat fetal adrenal glands at E12 (51) . Studies in primate fetal adrenal glands showed that human adrenal glands expressed CYP11A between 14 and 22 wk of gestation only in the fetal zone (FZ) and transitional zone (TZ) of the adrenal cortex, not in definitive zone (DZ) cells, and became detectable in the DZ after 23 wk (52, 53) . In late gestation, monkey adrenal expression of CYP11A was observed in all three zones (53) . Postnatally, adrenal CYP11A expression is essential for life (54, 55) .
B. CYP17
1. Reaction catalyzed. CYP17 (P450c17) catalyzes two mixedfunction oxidase reactions utilizing cytochrome P450 oxidoreductase and the microsomal electron transfer system (Fig. 2B) . The two reactions catalyzed by P450c17 are the 17␣-hydroxylation of the C21 steroids, pregnenolone (⌬ 5 steroid) or progesterone (⌬ 4 steroid), followed by the cleavage of the C17-20 bond to produce the C19 steroids, dehydroepiandrosterone (DHEA) or androstenedione, respectively (Fig. 4) . Each reaction requires one molecule of NADPH and one molecule of molecular O 2 . In this two-step reaction, 17␣-hydroxypregnenolone or 17␣-hydroxyprogesterone is formed as an intermediate. Initially, it was believed that each reaction was carried out by distinct enzymes. However, stud- ies by Hall and colleagues (56, 57) showed that a single purified protein catalyzed both 17␣-hydroxylation and C17-20 cleavage (lyase activity). Subsequent cloning of bovine P450c17 cDNA and expression of this cDNA confirmed that both reactions are catalyzed by a single protein (58) . Although the CYP17 enzyme from various species catalyzes both the hydroxylation and the lyase reaction, there are marked species-dependent differences in the utilization of either 17␣-hydroxypregnenolone (⌬ 5 ) or 17␣-hydroxyprogesterone (⌬ 4 ) as substrate for the lyase activity. The major species-dependent differences have been observed in C17-C20 lyase activity. The human and bovine enzymes prefer 17␣-hydroxypregnenolone as the substrate yielding DHEA as the product compared with the rodent enzyme that utilizes 17␣-hydroxyprogesterone as the substrate yielding androstenedione as the product (57) (58) (59) (60) (61) . These species-dependent differences in substrate preference are not related to differences in the aa sequence of the human, bovine, or rat enzyme, but are a property of the human and bovine enzyme for the requirement of the accessory protein cytochrome b 5 in promoting the lyase activity of 17␣-hydroxypregnenolone but not of 17␣-hydroxyprogesterone (61, 62) . Cytochrome b 5 is an accessory protein that acts as an allosteric effector of the CYP17-oxidoreductase complex, thus increasing the Vmax of the lyase activity (62) . Rat CYP17 lyase activity with 17␣-hydroxyprogesterone as substrate is also stimulated by b 5 , but the fold increase is small relative to the increase observed with the human enzyme (61).
2. Molecular structure. Genomic Southern blotting and/or cloning demonstrated that in mouse (63) , rat (64) , and human (65, 66) , as well as in other species (21, 67, 68) a single gene, CYP17, encodes CYP17. The Cyp17 gene is about 6 kb in length and contains eight exons with the location of intronexon boundaries conserved among species (69) . The 5Ј upstream region of the human (70 -73) , mouse (63) , and rat (64) CYP17 gene share high homology in the first 550 bp including the nonconsensus TATA box. The human CYP17 gene has been mapped to chromosome 10q24.3 (70, 71) , and the mouse Cyp17 gene has been mapped to chromosome 19 at 46 cM (63) . Human (72) CYP17 contains 508 aa compared with 507 aa found in mouse (63) and rat (64) proteins. The molecular mass of the CYP17 protein is approximately 57 kDa ( Table 1) . Comparison of the mouse aa sequence to rat and human aa sequences shows that they are 83 and 66% identical, respectively. The CYP17 protein of different species contains regions of high homology common to members of the P450 gene family (63) . These are the putative binding regions for mouse aa 434 -454 (63), human aa 435-455 (73) , and the ozols tridecapeptide sequence (343-372 aa) (74) that may play a role in substrate specificity (75) . Furthermore, there is a region specifically conserved among different species of CYP17 (296 -319 aa) that may function in catalysis (76) . Arginine 346 in the rat enzyme (77) and arginine 347 in the human enzyme (78) were found to be critical for catalyzing the lyase activity.
3. Tissue-and developmental-specific expression. CYP17 is expressed in all the classic steroidogenic tissues; however, there are species-related differences in the expression of this enzyme in the adrenal gland and placenta. In testis of all species, CYP17 is expressed solely in the Leydig cell (40, 79, 80) . In ovary, CYP17 expression is restricted to thecal cells that are the site of androgen production (81) (82) (83) (84) . The general consensus is that granulosa cells and luteal cells do not express CYP17 (81) (82) (83) (84) (85) . A recent report, however, suggests that human luteinized granulosa cells in culture do express CYP17 (86) . In the adrenal glands of human, bovine, macaque, and guinea pig, CYP17 is expressed in the zona reticularis and the zona fasciculata (87-89) but not in the zona glomerulosa, which is the site of aldosterone synthesis (90, 91) . CYP17 is not expressed in mouse (92) or rat adrenal glands (40, 61) . The adrenals of these animals produce corticosterone rather than cortisol that occurs in human and other species. CYP17 is not expressed in human placenta. The C19 substrate for placental androgens and estrogens is derived from fetal adrenal glands as DHEA sulfate that is converted to 16␣-hydroxydehydroepiandrosterone sulfate in the fetal liver and transported to the placenta, where it is acted on by placental steroid sulfatase (93) . In contrast, CYP17 is expressed in mouse and rat placenta starting at midpregnancy and declining just before parturition (32, 94) .
Expression of CYP17 has been studied in human (52, 53) and monkey fetal adrenal glands (53) . CYP17 mRNA and protein have been detected in the TZ and FZ throughout gestation, but not in the DZ. This differs somewhat from observations of the expression of CYP11A, which showed expression in the DZ after 23 wk gestation (52) . Fetal monkey adrenal glands from late gestation monkey fetuses exhibited a similar pattern of CYP17 in the FZ and TZ as observed in human fetal adrenal glands. CYP17 was not detected in the DZ of the monkey adrenals (53). Keeney et al. (95) reported detection of CYP17 mRNA in mouse fetal adrenal cells between E12.5 and E14.5, after which expression disappears and, as reported earlier, CYP17 is not expressed postnatally in the adrenal glands of mice (92) or rats (94, 95) . The expression of CYP17 mRNA in fetal mouse gonads follows the same expression pattern as observed for CYP11A (46) . CYP17 is expressed in mouse fetal testes from E13, the earliest time examined, and throughout pregnancy. No expression has been observed in mouse fetal ovary until the day of birth (46) . Expression of CYP17 in mouse testes postnatally is low between birth and 20 d, rising between 20 and 25 d, and reaching maximum expression after postnatal d 40 (50) .
C. CYP19
1. Reaction catalyzed. CYP19 (P450arom) catalyzes the conversion of the C19 androgens, androstenedione and testosterone, to the C18 estrogens, estrone and estradiol, respectively.
The reaction involves the microsomal electron transfer system, cytochrome P450 reductase, and three molecules each of oxygen and NADPH. The first two oxygen molecules are involved in the oxidation of the C19 methyl group by standard hydroxylation reactions, whereas the third oxygen molecule is used in a reaction postulated to be a peroxidative attack on the C19 methyl group combined with elimination of the 1␤ hydrogen to yield a phenolic A ring and formic acid ( 2. Molecular structure. CYP19 is the product of a single gene in human (12, 96) , rat (98) , and mouse (99) . The human gene, CYP19, has been mapped to 15q21.1 (100) , and the mouse Cyp19 is found on chromosome 9 at 31 cM (37). The human CYP19 gene contains 10 exons, nine of which comprise the coding region spanning approximately 30 kb (12) . Upstream of exon II are several alternative exon Is that are spliced into the 5Ј untranslated region that determines the tissue-specific expression of the protein (12) . These different exon Is are designated as exon Il, the placental-specific exon found 89 kb upstream of exon II; exon I.4 that determines expression in adipose, bone, and skin found 59 kb upstream of exon II; exon If, which is the brain-specific exon at 29 kb upstream of exon II; exon I.6, also involved in determining expression in bone, found approximately 0.7 kb upstream of exon II; and exon I.3 that is responsible for expression in adipose and breast cancer tissue located approximately 0.2 kb upstream of exon II (12) . The proximal promoter II determines gonadal expression of CYP19, and the transcript originates immediately upstream of the translational start site approximately 26 bp downstream of the putative TATA sequence (101) . Although the transcripts in the different tissues have different 5Ј termini, the coding region of the expressed protein is identical.
The deduced aa sequence of human CYP19 compared with rat and mouse shows 81% homology (96) . Both the human and the mouse protein consist of 503 aa having a molecular mass of 58 kDa (96). The CYP19 proteins of different species contain the same structural features described for the other cytochrome P450 enzymes: the heme-binding region containing a conserved cysteine residue that serves as the fifth coordinating ligand of the heme iron, and the substrate binding site in the amino-terminal I-helix region.
Tissue-and developmental-specific expression.
The expression of CYP19 is widely distributed. The major sites in humans (12) and rats (102) are in the preovulatory follicle, the corpus luteum of ovulatory humans, and the rat corpus luteum during the second half of pregnancy (102) . In human pregnancy, the placenta is the major site of CYP19 expression (103) . Rat and mouse placenta do not express CYP19 (103) . Other nonprimates such as bovine, porcine, and equine do express CYP19 in the placenta (103) . Testicular expression of CYP19 has been known for many years. In an early report, the testicular expression of aromatase was demonstrated by measuring the secretion of estradiol by human, simian, canine, and rat testes (104, 105) . The testicular site of CYP19 expression in the testis has been studied by several investigators. Studies on separated seminiferous tubules and intact testicular tissue from human testes indicated that the major site of aromatization in human testes is in the interstitial tissue (106) . Immunohistochemical studies in human testes showed that aromatase was detected in Leydig cells and absent in Sertoli cells in normal adult testes (107) . Studies investigating the testicular site of aromatization of testosterone to estradiol using rat testes or isolated testicular cells demonstrated that CYP19 was expressed in Leydig cells from 25-d-old and 60-to 70-d-old rats and, furthermore, that human chorionic gonadotropin (hCG) can acutely stimulate Leydig cell aromatization of testosterone to estradiol (108 -110) . Aromatization was demonstrated in Leydig cells from 15-d-old immature rats (110) . Studies by Dorrington and Khan (111) examining Sertoli cells from immature rat testes maintained in culture provided evidence for aromatase activity, with the highest expression in Sertoli cells from 5-dold rats with decreasing expression with age becoming essentially undetectable in rats aged 30 d and older. Taken together, the above-described studies indicate that there is a shift in the site of testicular somatic cell expression of CYP19 from Sertoli cells in neonatal rats to the Leydig cells of pubertal and mature rats. More recently, it has been established that aromatase is expressed in germ cells from the pachytene spermatocyte stage of rats and mice (reviewed in Ref. 112) . Indirect evidence for aromatase expression in human spermatozoa has been obtained from the measurements of estradiol levels in ejaculates (113) .
Expression of CYP19 mRNA during fetal development has been studied in humans and mice. Toda et al. (114) , studying the expression of CYP19 mRNA in various human fetal tissues, detected high expression in fetal liver with lower expression in fetal intestines and minute or no expression in skin, lung, kidney, adrenal, or brain. CYP19 mRNA is undetectable in adult human liver (114) . Harada and Yamada (115) , studying the expression of CYP19 mRNA in brain tissues of male and female mice during fetal and postnatal development, detected expression in total brain as early as 12 d gestational age, with rapidly increasing expression reaching maximal levels 4 d postnatally followed by a continuous decrease to adult levels. Expression of CYP19 mRNA in fetal gonads of mice was first detected in fetal testes at d 17 postcoital and in both male and female gonads 1 d postnatally (46) . For more detailed recent reviews on tissuespecific expression and regulation of CYP19, see Refs. 12 and 103. 
D. CYP21
1. Reaction catalyzed. CYP21 (P450c21) catalyzes the hydroxylation of C21 of progesterone and 17␣-hydroxyprogesterone yielding 11-deoxycorticosterone and 11-deoxycortisol, respectively. This reaction occurs in the endoplasmic reticulum and requires one molecule of NADPH and one molecule of oxygen and the microsomal electron transfer system (Fig. 6) . Progesterone is the substrate for CYP21 in the adrenal zona glomerulosa that does not express CYP17. C21 hydroxylation is the catalytic step that determines the biosynthesis of adrenal steroid hormones (Fig. 1) . 11-Deoxycorticosterone cannot serve as a substrate for hydroxylation at C17 by CYP17, thus 11-deoxycorticosterone cannot be an intermediate in the biosynthesis of cortisol.
2. Molecular structure. There are two genes, CYP21A and B, in human (116, 117) and mouse (118) that encode mRNA. In both species, the CYP21 genes are located in the major histocompatability locus and are duplicated in tandem with the C4A and C4B genes (119, 120) . In human, only the CYP21B gene encodes an active enzyme. The human CYP21A gene has an eight-base deletion, a one-base insertion, and a transition mutation that most likely results in the premature termination of translation (116, 117, 121) . In mouse, it is the Cyp21a gene that encodes the active enzyme (122) . The mouse Cyp21b gene has a 215-nucleotide deletion in the second exon, as well as other nucleotide changes that result in frame shifts and premature termination codons (120) . The two human genes consist of 10 exons and are found to be highly homologous including their introns and flanking regions (117) . The human genes are located on chromosome 6p21.3 (119) . The mouse genes are found on chromosome 17 at 18.77 cM. The open reading frame of the human and murine cDNA encode proteins of 495 and 487 aa, respectively, with a molecular mass of 56 kDa for human and 55.3 kDa for mouse protein (Table 1 ) (123).
Tissue-and developmental-specific expression.
CYP21 is exclusively expressed in the adrenal cortex and is essential for the synthesis of adrenal-specific steroids, the glucocorticoids, cortisol and corticosterone, and the mineralocorticoid, aldosterone (124, 125) . It is expressed in all three zones of the adrenal cortex-the zona reticularis, zona fasciculata, and zona glomerulosa. Expression has not been detected in kidney, liver, testis, or ovary (118) . The fetal primate adrenal gland differs in structure from the structure of the postnatal gland. It consists of three functional zones: 1) the outer DZ that does not appear to be involved in adrenal steroidogenesis; 2) the TZ, located between the inner FZ and the DZ; and 3) the FZ that expresses the enzymes required for DHEA synthesis, and thus, is responsible for supplying the substrate for placental estrogen synthesis. Coulter and Jaffe (126) examined the expression of the CYP21 protein by immunohistochemistry in human fetal adrenal glands between 13 and 24 wk gestation and in pregnant rhesus monkeys between 109 and 125, 134 and 156, and 159 and 172 d of pregnancy. Very few immunoreactive cells were detected in human adrenal DZ cells between 13 and 24 wk; however, expression was observed in all cells of the TZ and FZ. In the fetal adrenal glands of rhesus monkeys between 109 d and term, all three zones expressed the CYP21 protein, but expression was markedly reduced in the FZ relative to the DZ and TZ. Expression of CYP21 during human fetal development differs from the expression observed in the adult adrenal gland. In the adult adrenal gland, intense expression was observed in the zona glomerulosa and zona fasciculata, with little or no expression in the zona reticularis (126) .
In a more recent study, Narasaka et al. (52) examined the expression of steroidogenic enzymes by histochemical analysis of human fetal adrenal glands between 14 wk gestation and term. They report expression of CYP21 in the FZ and TZ between 14 wk and term and in the DZ starting at 24 wk and continuing to term.
E. CYP11B1 and B2
1. Reaction catalyzed. CYP11B1 and CYP11B2 (P450c11b1 and P450c11b2) are located in the inner mitochondrial membrane. CYP11B1 catalyzes the 11␤-hydroxylation of 11-deoxycorticosterone or 11-deoxycortisol yielding corticosterone or cortisol, respectively (Fig. 7) . CYP11B1 also has the capacity to hydroxylate C18 of 11-deoxycorticosterone or corticosterone to form 18-hydroxycorticosterone; however, it cannot catalyze the oxidation of the 18-hydroxy group to form aldosterone. Aldosterone synthesis from 11-deoxycorticosterone is catalyzed by CYP11B2, more commonly referred to as aldosterone synthase, which catalyzes three sequential reactions, each utilizing one molecule of NADPH and one molecule of oxygen and the mitochondrial electron transfer system. The three sequential reactions are: the 11␤-hydroxylation of 11-deoxycorticosterone, the hydroxylation of carbon 18, followed by oxidation of the carbon 18 hydroxyl group to yield the carbon 18 aldehyde group resulting in the formation of aldosterone (Fig. 8) . It is believed that the conversion of 11-deoxycorticosterone to aldosterone by CYP11B2 occurs without the release of the intermediates in a manner similar to the cleavage of cholesterol in the biosynthesis of preg- nenolone (127) . It also was reported that CYP11B2 does not utilize corticosterone efficiently as a substrate for aldosterone synthesis, thus providing additional evidence that the biosynthesis of aldosterone occurs with 11-deoxycorticosterone as substrate and the catalysis is solely mediated by CYP11B2 and does not involve the sequential action of CYP11B1 followed by CYP11B2 (128) . In rat, three CYP11B enzymes have been characterized, CYP11B1, B2, and B3 (129). The reactions catalyzed by B1 and B2 are the same as described above for the human and mouse enzymes. B3 can convert deoxycorticosterone to 18-hydroxycorticosterone, but lacks 18 oxidase activity and thus cannot synthesize aldosterone (129).
2. Molecular structure. CYP11B1 and CYP11B2 are located on human chromosome 8q21-22 (127, 130) . These two genes are closely linked, separated by approximately 40 kb (131). The two genes in mouse found on chromosome 15 are separated by approximately 8 kb (11). The two genes in both mouse (11) and human (132) are found with the B2 gene 5Ј of the B1 gene and are oriented so that both genes are transcribed in the same direction. Each of the genes consists of nine exons and comprises about 7 kb (127, 130). The two human genes are highly homologous, with nucleotide sequences of CYP11B1 and 11B2 exhibiting 95% identity in the coding sequence and about 90% identity in the intron sequence. Interestingly, the location of the introns in human genes is identical to the location of the introns of the CYP11A gene that encodes the CYP11A protein and accounts for the inclusion of these three CYP genes as members of the same P450 gene superfamily, i.e., CYP11 (130). The two mouse genes, Cyp11b1 and Cyp11b2, exhibit an overall identity of 84% in the coding region (11) . In mouse and human genes, the sequence in the three regions-the heme binding domain, the aromatic region, and the region comprising the ozol peptide, which are highly conserved in all P450 steroidogenic enzymes-is essentially identical (11) . In rat, four CYP11B genes have been identified as CYP11B1, -B2, -B3, and -B4 (129, 133). B1, B2, and B3 have similar structures consisting of nine exons, the same as human and mouse genes (133). The location of the introns in each of these three genes is identical. The B4 gene lacks the exon 3 sequence and part of the exon 4 sequence found in other rat CYP11B genes, and thus, is believed to be a pseudogene (133). The nucleotide sequence homology in the coding region of B1 to B2, B1 to B3, and B2 to B3 was reported to be 88, 96, and 86%, respectively (133).
The aa sequences of the human CYP11B1 and B2 are 93% identical (127) . The proteins are located in the inner mitochondrial membrane and thus are synthesized including a leader sequence of 24 aa that is cleaved in the mitochondria to yield a protein of 479 aa in human and 476 aa in mouse. Although CYP11B1 and B2 consist of the same number of aa when separated by SDS-PAGE, the apparent molecular mass of the human enzymes was reported as 51 and 49 kDa, respectively (127) , and the rat enzymes as 51.5 and 49.5 kDa, respectively (134).
Tissue-and developmental-specific expression.
Expression of CYP11B1 and B2 is limited to the adrenal cortex. B2 appears to be expressed exclusively in adrenal zona glomerulosa cells, whereas the major site of CYP11B1 is in the adrenal zona fasciculata/reticularis, with some expression of B1 also observed in mitochondria of the adrenal zona glomerulosa (10, 134) . Expression of CYP11B1 appears to be severalfold greater than expression of B2 in both human and rat adrenal glands (10, 135) . In contrast, Domalik et al. (11) , examining mouse adrenal cortex sections by in situ hybridization, found similar expression of the two CYP11B isoforms, with CYP11B1 expressed exclusively in the zona fasciculata/reticularis and CYP11B2 expressed exclusively in the zona glomerulosa. Rat CYP11B3 mRNA is expressed in the zona fasciculata/reticularis and not in the zona glomerulosa (129). However, developmental expression of rat CYP11B3 differs from that of CYP11B1 as described below (129).
Developmental expression of immunoreactive CYP11B1 and B2 in primate fetal adrenal glands has been studied by Coulter and Jaffe (126) . The study did not differentiate between the expression of the B1 and B2 proteins due to the unavailability of an antibody that can distinguish between these two enzymes. Coulter and Jaffe examined human fetal adrenal glands between 13 and 24 wk gestation and fetal adrenal glands from rhesus monkeys from 109 d gestation to term. CYP11B1/B2 in the human fetal adrenal glands was absent in the DZ, but present in the TZ and FZ with higher expression in the FZ than the TZ. In the fetal rhesus monkey between 109 d and term, the B1/B2 protein was detected in all cells of the TZ and FZ, but absent in the DZ until near term. Metapyrone-induced ACTH stimulation in the rhesus monkey increased expression of the enzymes in the TZ and FZ and induced expression in the DZ (126) . Developmental expression of CYP11B1, B2, and B3 mRNAs in rat adrenal glands between neonatal d 2 and 18 and from adult rats exhibit distinct expression patterns (129). Adrenal glands from neonatal d 2 exhibited a relatively large amount of B1 mRNA, with barely detectable B2 and no detectable B3 mRNA. At 10 d, B1 mRNA was markedly reduced, and B3 became the major CYP11B mRNA. This pattern of expression was found in adrenal glands until postnatal d 18 with no differences observed in expression in glands from male and female pups. In adrenal glands from mature rats, B3 expression is considerably less than B1.
F. Regulation of expression of the cytochrome P450 steroidogenic enzymes
A major nuclear factor that determines cell-specific expression of P450 steroidogenic enzymes in gonads and adrenal glands was identified in two laboratories in 1992. This nuclear DNA-binding protein, referred to as SF-1 by Lala et al. (19) or Ad4BP by Morohashi et al. (20) , belongs to the orphan nuclear receptor family and binds to variants of an AGGTCA sequence motif found in the proximal promoter of all P450 steroidogenic enzymes (136). Although SF-1 is essential for cell-specific gonadal and adrenal expression, other factors are necessary for determining both maximal and cellspecific expression of these enzymes. Adrenal-specific expression of the CYP21 genes in both human (125) and mouse (137) is mediated by cell-specific elements located within the corresponding C4B and C4A genes. Three SF-1 sites have been identified within this distant promoter of the human CYP21 gene.
Chronic, but not acute, stimulation by pituitary peptide hormones (ACTH in the adrenal zona reticularis and zona fasciculata; LH in ovarian theca, corpus lutea, and testicular Leydig cells; and FSH in ovarian granulosa cells), acting via G protein-coupled receptors, activates adenylate cyclase thereby increasing cAMP, which in turn, leads to increased synthesis of the steroidogenic P450 enzymes specific for these cells [reviewed for bovine P450 enzymes by Waterman (138) and Waterman and Keeney (139)]. The regulation of hormonal stimulation via cAMP leading to increased synthesis of these enzymes, with some exceptions described below, is not mediated by the cAMP response element (CRE)/CRE binding protein (CREB) system. cAMP responsive sequences found in the promoters of steroidogenic CYP genes expressing these enzymes differ among genes and among the same genes of different species (69, 136, 139) . The bovine CYP11B gene does contain a canonical CRE element in its promoter, which was shown to be required for cAMP-stimulated transcription (139, 140). In addition, it has been reported that cAMP acts via CRE/CREB in the rat CYP19 promoter (141) and in the PII human CYP19 promoter expressed in granulosa cells (142). Although, hormone-stimulated increases in cAMP enhance the expression of all of the steroidogenic P450 enzymes, additional factors are involved in maintaining maximal expression, with the exception of CYP17 whose expression appears to be entirely dependent on cAMP stimulation (138, 143).
CYP11B2 transcription, which is essential for aldosterone synthesis, is stimulated by angiotensin II, and by potassium ions that act by increasing the intracellular concentration of calcium ions (Ca 2ϩ ) (144). Furthermore, it was reported that cAMP can independently increase CYP11B2 transcription and that intracellular Ca 2ϩ and cAMP act via the same elements in the proximal promoter of the human CYP11B2 gene (144). Two elements located at Ϫ71/Ϫ64 and Ϫ129/Ϫ114 are required for both basal and maximal induction by either cAMP or Ca 2ϩ . The Ϫ71/Ϫ64 sequence resembles a consensus CRE/CREB element; the other element, Ϫ129/Ϫ114, binds SF-1 and the chicken ovalbumin upstream promoter transcription factor (144). Thus, increases in either cAMP or intracellular Ca 2ϩ can independently increase transcription of the human CYP11B2 gene. These studies would indicate that the protein kinase C (PKC) pathway is not involved in mediating aldosterone-stimulated increases in CYP11B2 transcription. In a recent study, Bassett et al. (145) reported that although the CYP11B2 promoter contains a binding site for SF-1, SF-1 does not appear to be involved in the transcriptional regulation of CYP11B2.
Human placenta expresses two cytochrome P450 enzymes, CYP11A and CYP19. The placental-specific expression of these enzymes is dependent on factors distinct from those regulating expression in gonadal and adrenal cells. SF-1, which is essential for expression of these enzymes in adrenal and gonadal cells, is not present in human placenta (146). Identification of factors regulating the placentalspecific expression of human CYP11A has long been sought. Hum et al. (147) identified a 55-kDa protein that appeared to act as a transacting factor for CYP11A expression in placental cells, but not in adrenal cells. However, this nuclear protein also was found in other nonsteroidogenic cells that do not express CYP11A (147). In a subsequent investigation, Huang and Miller (148) identified two transcription factors related to HIV-inducible LBP proteins, LBP-1B and LBP-9, that could modulate expression of human CYP11A in placenta but were not involved in determining its placental-specific expression. A recent study reported the isolation of a placental-specific nuclear protein that specifically binds to a conserved proximal region, SCC1, in the promoter of the human, rat, mouse, ovine, bovine, and porcine CYP11A gene (44) . This placental nuclear protein turned out to be activating protein 2 (AP-2). The major AP-2 in human was AP-2␣ and in mouse giant trophoblast cells, AP-2␥. Interestingly, the AP-2 binding sequence overlaps with the previously identified SF-1 sequence that determines the gonadal-and adrenal-specific expression of CYP11A. The authors demonstrated that coexpression of the rat promoter containing the SCC1 sequence with an AP-2␣ or AP-2␥ expression vector markedly increased transcriptional activity (44) . It remains to be shown whether AP-2 factors are involved in the expression of CYP11A in human placenta and whether additional factors to AP-2 are required for determining the placental-specific expression of CYP11A.
Placental expression of CYP19 in human and nonhuman primates, ungulates, and rabbits is under the control of a placental-specific exon 1 (103) . The placental-specific exon for human has been described above. CYP19 is not expressed in the placenta of either mouse or rat (12) . Relatively little is known regarding the transcription factors that determine placental-specific expression of CYP19. Kamat et al. (149, 150) showed that elements within 501 bp of the proximal promoter flanking the placental-specific exon 1.1 determine placental-specific expression. From their studies, they conclude that this region contains both placental-specific positive elements and specific sequences that bind inhibitory transcription factors in nontrophoblast cells. Yamada et al. (151) identified a glia cell missing placental transcription factor that binds specifically to an element within 205 bp of the placental-specific promoter and may be involved in determining the placental-specific expression of CYP19.
III. Hydroxysteroid Dehydrogenases
The hydroxysteroid dehydrogenases, which include the 3␤HSDs and the 17␤HSDs, belong to the same phylogenetic protein family, namely the short-chain alcohol dehydrogenase reductase superfamily 1 (152) . They are involved in the reduction and oxidation of steroid hormones requiring NAD ϩ /NADP ϩ as acceptors and their reduced forms as donors of reducing equivalents. One of the major differences between the P450 enzymes and the hydroxysteroid dehydrogenases is that each of the P450 enzymes is a product of a single gene, whereas there are several isoforms for the 3␤HSDs and several isozymes of the 17␤HSDs, each a product of a distinct gene. The number of isoforms or isozymes varies in different species, in tissue distribution, catalytic activity (whether they function predominantly as dehydrogenases or reductases), substrate and cofactor specificity, and subcellular localization.
A. 3␤-Hydroxysteroid dehydrogenase/isomerase
3␤HSD/isomerases are membrane-bound enzymes and are distributed to both mitochondrial and microsomal membranes depending on the type of cell in which they are expressed (see Section III.A.3). During the past decade, multiple isoforms of 3␤HSDs have been isolated and characterized in human (153) , mouse (7, 154) , and rat (8, 155, 156) . The different isoforms are numbered in the order in which they were identified; therefore, the same numeral in different species does not indicate that they are orthologous (see Table 2 for human and mouse isoforms). The largest number of isoforms (six) was identified in mouse. These isoforms are highly homologous in their aa sequence, but fall into two distinct functional groups. Mouse 3␤HSD I, III, and VI function as classic dehydrogenase/isomerases (see Section III.A.2), whereas mouse 3␤HSD IV and V function exclusively as 3-ketosteroid reductases, are not involved in active steroid hormone biosynthesis (5, 6) , and thus will not be discussed further in this review.
The enzymatic action of the 3␤HSD/isomerases are essential for the production of all active steroid hormones. Active steroid hormones are ⌬ 4 -3-ketosteroids, progesterone, testosterone, cortisol, or aldosterone, or are derived from a ⌬ 4 -3-ketosteroid, estradiol (Fig. 5) . Two distinct isoforms have been identified in humans, human 3␤HSD I and II. Both of these isoforms function as steroid dehydrogenase/isomerases. In this review, human 3␤HSD I and II and mouse 3␤HSD I and VI will be described, because these are the sole isoforms involved in the biosynthesis of all active steroid hormones.
1. Reaction catalyzed. Human 3␤HSD I and II and mouse 3␤HSD I and VI catalyze the conversion of the ⌬ 5 -3␤-hydroxysteroids, pregnenolone, 17␣-hydroxypregnenolone, and DHEA to the ⌬ 4 -3-ketosteroids, progesterone, 17␣-hydroxyprogesterone, and androstenedione, respectively. Two sequential reactions are involved in the conversion of the ⌬ 5 -3␤-hydroxysteroid to a ⌬ 4 -3-ketosteroid. The first reaction is the dehydrogenation of the 3␤-equatorial hydroxysteroid requiring the coenzyme NAD ϩ yielding a ⌬ 5 -3-keto intermediate and reduced NADH. The reduced coenzyme, NADH, then activates the isomerization of the ⌬ 5 -3-ketosteroid to yield the ⌬ 4 -3-ketosteroid ( Fig. 9 ) (157) (158) (159) . This reaction is catalyzed by a single dimeric protein without the release of the intermediate or coenzyme (159) . Human and mouse enzymes also have the capacity to convert 5␣-androstane-3␤,17␤-diol to dihydrotestosterone in the presence of NAD ϩ (2, 3, 160). NADP ϩ was reported to be relatively ineffective as a cofactor for these reactions (160) . Comparison of K m values for the expressed human and mouse isoforms demonstrated that K m values for mouse 3␤HSD VI were lower than for mouse 3␤HSD I with pregnenolone as a substrate (7). Similar results were reported for expressed human 3␤HSD I compared with expressed human 3␤HSD II (2, 161).
2. Molecular structure. As mentioned above, there are two isoforms of 3␤HSD in human and six isoforms in mouse. Each of these isoforms is the product of a distinct gene. Mouse Hsd3b genes are located in a cluster on mouse chromosome 3 close to the centromeric region that shows conservation of gene order and physical distance with the centromeric region of human chromosome 1 (4, 162) . Human HSD3B genes are found on chromosome 1p13.1 and, as predicted from the studies by Bain et al. (4) , were found close to the centromeric marker D1Z5 (163, 164) . All of the HSD3B genes isolated to date consist of four exons, with the start site of translation found in exon 2 (162) . The two human genes are approximately 7.8 kb, and comparison of their nucleotide sequences indicates that they are highly homologous, not only in the sequence of the exons, but also in their intronic sequences as well as in the 1250 bp sequence of the 5Ј flanking region that exhibits 81.9% identity (153) . The size of the mouse Hsd3b genes varies due to differences in the size of their introns (162, 165) . The greatest difference in the mouse genes was found in the size of intron 1 of the mouse Hsd3b6 gene that was determined to be 3.1 kb (165) compared with 126, 125, and 132 bp found in intron 1 of mouse Hsd3b1 and human HSD3B1and HSD3B2, respectively (162) . The open reading frames of human I, mouse I, and mouse VI 3␤HSD encode a protein including the initiator methionine of 373 aa, whereas human 3␤HSD II encodes a protein of 372 aa (7, 153) . The aa sequences among the isoforms and between the mouse and human isoforms show a high degree of identity. Mouse 3␤HSD I is 84% identical to mouse 3␤HSD VI, and 72 and 71% identical to human 3␤HSD I and II, respectively (5, 7). Although the aa sequence predicts a molecular mass of 42 kDa for all of the proteins, when separated by SDS-PAGE, the mobilities of mouse 3␤HSD I and VI are distinct, exhibiting an apparent molecular mass of 42 and 44 kDa, respectively (7). The cofactor binding site is found in the amino-terminal sequence. Homology modeling studies showed that Asp 36 in human 3␤HSD I is responsible for the NAD(H) binding site (159) . In earlier studies investigating the difference in the aa sequence of mouse 3␤HSD I, which requires NAD ϩ as a cofactor, and mouse 3␤HSD IV and V, which require NADP ϩ as cofactor, it was found that Asp 36 was essential for NAD ϩ -mediated dehydrogenation/isomerization and that the replacement of Asp 36 with phenylalanine at position 36 changed the cofactor specificity to NADP ϩ (6, 154). The dehydrogenase activity has been localized to the Y 154 -P-H-S-K 158 domain and the isomerase site to Tyr 269 and Lys 273 of the human 3␤HSD protein (161).
Tissue-and developmental-specific expression.
The isoforms of 3␤HSD are expressed in a cell-and tissue-specific manner. The expression of human 3␤HSD isoforms examined by RNase protection analysis demonstrated that human 3␤HSD I is expressed in placenta, skin, and breast tissue, whereas 3␤HSD II is expressed in adrenal gland, ovary, and testis (2, 153) . A similar distribution of expression of the two orthologous mouse isoforms was demonstrated with mouse 3␤HSD I expressed in testis, ovary, and adrenal gland, and 3␤HSD VI observed in placenta and skin, as well as in testis (7). In situ hybridization in mouse testicular sections demonstrated the exclusive expression of 3␤HSD in the Leydig cells of the testis (166, 167) . The expression of 3␤HSD VI mRNA and protein was demonstrated during early pregnancy in mouse (32) . 3␤HSD mRNA and protein were observed in decidual cells after implantation until E7.5 and are observed in giant trophoblast cells at E8.5, reaching a maximum between E9.5 and E10.5 and thereafter decreasing to undetectable levels (32, 165, 167) . Immunochemical localization of 3␤HSD was examined in sections of rat adrenal glands and gonads (40) . 3␤HSD was seen in secretory cells of the zona reticularis and the zona glomerulosa. Immunolabeling was detected mostly in the endoplasmic reticulum, but also over the vesicular crista membranes of the mitochondria (40) . As demonstrated in mouse testis, 3␤HSD was exclusively detected in the Leydig cell. According to studies by Pelletier et al. (40) , immunostaining for 3␤HSD was found exclusively in the mitochondria of the Leydig cell. The intramitochondrial localization of 3␤HSD has been confirmed in bovine adrenal glomerulosa cells and rat adrenal fasciculata cells (168 -170) . In rat ovary, 3␤HSD was detected in thecal and granulosa cells of growing and preovulatory follicles with no detection observed in primary follicles. High expression was seen in interstitial and luteal cells. Immunoreactivity was detected mostly in the endoplasmic reticulum, with some labeling in the crista membranes of the mitochondria (40) . Expression of 3␤HSD during fetal and neonatal development has been examined most extensively in mouse testis. Expression of 3␤HSD in fetal gonads was first examined between E13 and postnatal d 1 (46) (166) . In studies reported by Payne and colleagues (7, 167) , 3␤HSD I mRNA or protein always was found to be the predominant isoform in adult testes. In their investigations examining fetal human adrenal glands during midgestation by immunohistochemistry and in situ hybridization, Mesiano et al. (53) could not detect expression of 3␤HSD in any of the samples examined. However, expression was detected during late gestation in the monkey fetal adrenal gland. 3␤HSD was detected in the DZ with some expression in the TZ. Narasaka et al. (52) could not detect immunoreactive 3␤HSD in any cortical zones of human fetal adrenal glands before 22 wk gestation; however, after 23 wk gestation, expression was discernible in the TZ and DZ, but not in the FZ. The lack of expression of adrenal 3␤HSD in the human fetal adrenal zone explains the lack of synthesis of cortisol and aldosterone by human fetal adrenals until late during gestation. Immunohistochemical studies on the expression of 3␤HSD in human adrenal glands obtained between the ages of 7 months and 62 yr detected expression in all three adrenal zones between 7 months and 8 yr followed by a decrease in the zona reticularis with increasing age (171) .
B. Regulation of expression of 3␤HSDs
The gonadal-and adrenal-specific expression of human 3␤HSD II and mouse 3␤HSD I also appears to be dependent on the SF-1 as described for the gonadal-and adrenal-specific expression of the P450 steroidogenic enzymes. Leers-Sucheta et al. (172) identified an SF-1 response element in the proximal promoter of the HSD3B2 gene that conferred adrenalspecific expression of the gene. In addition, these authors reported that this SF-1 response element also was found to be essential for mediating phorbal ester-induced transcriptional activity. An earlier study on the analysis of the mouse Hsd3b1 promoter identified three potential SF-1 consensus binding sites in the proximal promoter (162) . In a subsequent study, it was shown that SF-1 also was required for the expression of mouse Hsd3b1 (165) . In contrast, expression of human 3␤HSD I and mouse 3␤HSD VI is not dependent on SF-1 (165). These two isoforms are essential for the biosynthesis of progesterone in human placenta and in mouse giant trophoblast cells, respectively. As described above, SF-1 is not expressed in either human or mouse placenta (146, 173). However, two transcription factors have been identified that determine the specific expression of mouse 3␤HSD VI in giant trophoblast cells in midpregnancy. These two factors are AP-2␥, the same factor identified as that which determines trophoblast-specific expression of CYP11A, and another mouse trophoblast-specific transcription factor, Dlx 3 (165) . These transcription factors are also expressed in human placenta. However, recent studies found that placentalspecific expression of human 3␤HSD I is not mediated by either AP-2 or Dlx-3, but by transcription enhancer factor-5 and a GATA-like protein (174) .
Tremblay and Beaudoin (175) reported that cAMP and phorbol myristate acetate increased the expression of 3␤HSD I mRNA in human JEG-3 cells and that the increase mediated via these two signaling pathways was additive. Subsequent studies with human 3␤HSD II promoter constructs in human adrenal cortical (H295R) cells demonstrated marked increases in transcriptional activity after treatment with phorbol ester and, as discussed above, maximal effect of phorbol ester was dependent on the presence of SF-1 (172) . Additional studies on the regulation of 3␤HSD in the H295R cells demonstrated that treatment with the glucocorticoid receptor agonist, dexamethasone, increased the expression of 3␤HSD mRNA and that this effect was additive to the increase observed with phorbol ester treatment (176) . This effect of dexamethasone on 3␤HSD transcriptional activity involved Stat5A and the Stat5A response element. Additional studies by the same investigators reported that epidermal growth factor and prolactin also increase the transcriptional activity of the human 3␤HSD II promoter and that the effect of each of these hormones involves the Stat5A response element in the type II promoter (177, 178) . Investigations on the regulation of 3␤HSD expression in gonads have been limited mostly to studies in rodents. In vitro studies in cultured granulosa cells from immature rats showed that treatment with FSH increased rat 3␤HSD I mRNA, protein, and enzymatic activity (179) . Furthermore, treatment with IGF-I enhanced the FSH-induced increase (179, 180) . Eimerl and Orly (180) reported a high constitutive expression of 3␤HSD mRNA in granulosa cells that could be increased by treatment with FSH. In addition, they observed that IGF-I in the absence of FSH had the capacity to increase 3␤HSD mRNA that was distinct from their observations with the effect of IGF on increasing CYP11A mRNA that could only be observed in the presence of FSH. The role of gonadotropin and prolactin on ovarian 3␤HSD expression was investigated in hypophysectomized rats (181) . These investigators found that in vivo treatment with hCG for 2, 3, and 9 d induced increases in 3␤HSD mRNA expression by 63, 145, and 146%, respectively, above the control levels in ovarian interstitial cells only. In contrast, treatment with prolactin resulted in a marked decrease in 3␤HSD mRNA in the corpus luteum.
In studies on the regulation of 3␤HSD mRNA in mouse Leydig cells in culture, it was shown that these cells exhibit high constitutive expression of 3␤HSD (182) . Treatment with cAMP results in a marked decrease in the expression of 3␤HSD mRNA that could be reversed in the presence of aminoglutethimide, an inhibitor of cholesterol metabolism. It was demonstrated that testosterone produced during treatment of Leydig cells with cAMP repressed the cAMP induction of 3␤HSD mRNA (182) . Furthermore, the glucocorticoid agonist, dexamethasone, negatively regulated 3␤HSD expression. Studies in rat Leydig cells in culture demonstrated that treatment with LH, forskolin, or cAMP increased 3␤HSD mRNA, protein, and activity after 24 -72 h of treatment (183) . Investigations using gonadotropin-deficient mice to study the role of LH/hCG in regulating the expression of 3␤HSD I and VI mRNA in the adult Leydig cell lineage showed that the expression of 3␤HSD I was independent of LH stimulation (184) . In contrast, the expression of 3␤HSD VI mRNA was highly dependent on LH/hCG stimulation.
C. 17␤-Hydroxysteroid dehydrogenases
Like 3␤HSDs, the 17HSDs play essential roles in steroidogenesis. These enzymes catalyze the final step in the biosynthesis of active gonadal steroid hormones, estradiol, and testosterone, and unlike other steroidogenic enzymes described in this review, 17HSDs are not involved in the biosynthesis of adrenal steroids. The 17␤HSDs convert inactive 17-ketosteroids into their active 17␤-hydroxy forms. Although in in vitro studies these enzymes can function as either reductases or oxidases of the 17-keto group, in intact cells they function in a unidirectional manner (185) . The 17HSDs are found as either membrane-bound or soluble enzymes ( Table 2 ). To date, 11 different 17HSDs have been identified. So far, in human, nine different 17HSDs have been cloned, 1-5, 7, 8, 10, and 11 (9) . Unlike the 3␤HSDs described above, there is very little homology among the different 17HSD isozymes. The 17HSDs differ in tissue distribution, catalytic preferences, substrate specificity, subcellular localization, and mechanisms of regulation. Among the many different forms of 17HSDs, three forms participate in the final step of biosynthesis of active steroid hormones in gonads, types 1, 3, and 7, and therefore will be the only types discussed in this review. For discussion of the other types of 17HSDs, see reviews in Refs. 9 and 185-187.
The recently introduced nomenclature for 17HSD is based on the genetic identity of the enzymes and their functionality. Furthermore, the 17HSDs were numbered chronologically as they were identified. Among species, orthologs are assigned the same number; for example, type 4 17HSDs in human, rodent, guinea pig, pig, or chicken are all orthologs of the same enzyme. The canonical gene name for 17HSDs is HSD17Bn (in human) and Hsd17bn (in other species) where "n" represents the enzyme type number (e.g., enzyme 17HSD type 1 corresponds to the HSD17B1 gene). However, several recently discovered 17HSDs initially were assigned other gene names because a different functionality was studied (9).
1. 17HSD1. Type 1 17HSD was the first of the 17HSD/ketosteroid reductases to be cloned and characterized. 17HSD1 was first purified from human placenta by Jarabak et al. (188, 189) . It was cloned originally from a human placental library and subsequently found to be expressed in ovary and the mammary gland (185).
a. Reaction catalyzed. Human 17HSD1 has substrate specificity for estrogens, whereas the rodent enzyme can utilize both estrogens and androgens; NADPH is the preferred cofactor for conversion of estrone to estradiol (Fig. 10) (152,  186) . Human 17HSD1 has a 100-fold higher affinity for C18 than for C19 substrates. Whereas human 17HSD1 predominantly catalyzes the conversion of estrone to estradiol, mouse and rat 17HSD1 also efficiently convert androstenedione to testosterone (190) .
b. Molecular structure. The human gene, HSD17B1, maps to chromosome 17q11-q21 and encodes a 327-aa protein having a calculated molecular mass of 34.9 kDa with no membrane spanning domains (152, 191, 192) . The mouse gene, mHsd17b1, maps to chromosome 11 and encodes a 344-aa protein with a predicted molecular mass of 36.8 kDa (193) . The human 17HSDB1 gene is located in tandem with hHSD17BP1, a putative pseudogene. The hHSD17B1 gene is transcribed as two mRNA transcripts of 1.3 and 2.3 kb, due to two transcription start sites. Only the expression of the shorter transcript is correlated with changes in 17HSD1 protein levels (194, 195) . The mouse 17HSD1 shares 63% overall identity with human 17HSD1, and the most striking differences between the mouse and human type-1 enzymes are between aa residues 197 and 230 and in the carboxy terminus of the enzymes.
17HSD1 is a member of the short-chain alcohol dehydrogenase reductase (SDR) superfamily. The three-dimensional structure was solved in 1995 (196) . The 17HSD1 protein exists as a homodimer, consisting of noncovalently bound but tightly associated subunits; stable dimerization of the enzyme is required for its enzymatic activity (194) . The x-ray structure of the dimer indicates that there are two dimerization helices in each monomer forming a four-helix bundle (196) . Disruption of the helices by site-directed mutagenesis of specific aa results in improper folding and aggregation (197) .
17HSD1 shares less than 15% homology with bacterial 3␣,20␤HSD, the prototypical member of the SDR superfamily. Despite the limited sequence homology, the crystal structure of 17HSD1 revealed a fold characteristic of other SDRs (196) . The active site contains the pentapeptide Tyr-xxx-Lys and a serine residue in nearly identical locations relative to these residues in 3␣,20␤HSD that are conserved in all members of the SDR family. Together, the conserved pentapeptide and the cofactor and substrate binding sites comprise the catalytic triad of all members of the SDR (194) . The tyrosine residue plays a critical role in the catalytic reaction as a proton donor. The lysine residue is postulated to stabilize FIG. 10 . Enzymatic reaction catalyzed by 17HSD isozymes. Human type I uses estrone as substrate and acts predominantly as a reductase, whereas the rat type I can use estrone and androstenedione equally as substrate (190) . Type III acts predominantly as a reductase and preferentially uses androstenedione as substrate (209) . Type VII acts predominantly as a reductase and preferentially uses estrone as substrate (201, 202) .
cofactor binding by interacting with the hydroxyl groups of the nicotinamide ribose (197) .
The structure of 17HSD1 also contains three ␣-helices and a helix-turn-helix motif not observed in other reported structures of the SDRs. The inserted helices, which are located at one end of the substrate-binding cleft away from the catalytic triad, restrict access to the active site and appear to influence substrate specificity (196, 198) . When estradiol is docked in the substrate-binding site with the 17-hydroxyl oriented toward the catalytic triad, the steroid molecule fits properly in the pocket. The histidine on the helical insert of residues 209 to 229 can form a hydrogen bond to oxygen at position 3 of the steroid A-ring, thus creating specific binding of estranes and androstanes (196, 198) . Site-directed mutagenesis of His-221 demonstrated that this residue is essential for catalytic activity (199) . The cofactor binding sites in 17HSD1 and 3␣,20␤HSD also are conserved, with the insertions in the protein backbone of 17HSD1 at the distal end of the binding pocket away from the cofactor binding site. The insertions reduce the openness of the binding pocket to introduce substrate-binding specificity. By analyzing various rat and human chimeric proteins, together with site-directed mutation analysis, the difference in substrate specificity between human and rat 17HSD1 was revealed to be due to several aa variations at the recognition end of the catalytic cleft that alters the preference for neutral vs. phenolic substrates (190) . Solving the structure of the ternary complex of 17HSD1 with the cofactor NADP ϩ and the antiestrogen equilin revealed the details of the binding of the inhibitor in the active site of the enzyme and further elucidated the possible roles of various aa in the catalytic cleft (198) . The current model predicts that the hydroxyl groups of the conserved serine and tyrosine in the active site form a triangular hydrogen bond network enabling hydride transfer and reduction of estrone (194) . Furthermore, the three-dimensional structure revealed not only the position of the catalytic triad as well as the molecular mechanism of inhibition and the basis for substrate selectivity, but also a possible mechanism of ketohydroxyl interconversion (196, 198) .
c. Tissue-and developmental-specific expression. 17HSD1 is abundantly expressed in the granulosa cells of developing follicles and in human, but not rodent, placenta. Immunoreactive 17HSD1 protein has been confirmed in the syncytiotrophoblast of human placenta and in granulosa cells of human ovary.
17HSD7.
Estradiol production in the ovary is dependent on the action of 17␤HSD. In ovarian granulosa cells of developing follicles in cycling humans and rodents, 17HSD1 converts estrone to estradiol. Upon ovulation, follicles luteinize and transform into corpora lutea and continue to secrete estradiol at high concentrations although, upon luteinization, 17HSD1 expression declines precipitously in the ovary. The discovery of 17HSD7 explained the apparent paradoxical conversion of estrone to estradiol in the absence of 17HSD1. During the luteal phase of the ovarian cycle, estradiol is secreted mainly from the corpus luteum, where 17HSD7, not 17HSD1, is responsible for the final step in estradiol synthesis (200 -202) .
a. Reaction catalyzed. 17HSD7 is a membrane-associated reductive enzyme belonging to the SDR family. 17HSD7 catalyzes the conversion of estrone to estradiol and prefers NADPH as a cofactor (Fig. 10) . The human and rodent forms of the enzyme efficiently catalyze the conversion of estrone to estradiol (201, 203) .
b. Molecular structure. The human gene, HSD17B7, consists of nine exons and eight introns, spanning 21.8 kb, and was reported by Krazeisen et al. (203) to be located on chromosome 10p11.2. Human cDNA encodes a 37-kDa protein that shows 78 and 74% aa identity with rat and mouse, respectively. The exon/intron organization of human 17HSDB7 was found to be the same by two groups that reported on its cloning, Krazeisen et al. (203) and Breitling et al. (204) . The mouse gene, mHsd17b7, maps to chromosome 1. The mouse cDNA is 1.7 kb and encodes a peptide of 344 aa residues with a predicted molecular mass of 36.8 kDa (201) . 17HSD7 was originally identified by Gibori and coworkers (205) (206) (207) as prolactin receptor-associated protein (PRAP). However, subsequent cloning of mouse 17HSD7 indicated that rat PRAP and mouse 17HSD7 shared 89% identity, and further characterization of mouse 17HSD7 and PRAP determined that PRAP represented rat 17HSD7 (201) . Recently, Torn et al. (208) cloned a human 17HSDB7 that they localized to chromosome 1q23. They also identified and localized a pseudogene to 1q44. In this more recent report, Torn et al. (208) determined that the originally published chromosomal location of 17HSD7, 10p11.2, reported by Krazeisen et al. (203) corresponds to a homologous gene with several aa differences and a premature stop codon caused by a change in the reading frame of exon 5.
Predicted aa identity of the m17HSD7 compared with other m17HSD enzymes is only between 18 and 28%, which is characteristic of members of the SDR family. In addition, m17HSD7 contains the three critical residues, Ser 180 , Tyr 193 , and Lys 197 , of the catalytic triad as well as the glycine pattern, Gly 9 -X-X-X-Gly 13 -X-Gly 15 , all of which are involved in cofactor binding, required for catalytic activity and characteristic of SDR enzymes (190, 194, 196, 197, 201) .
c. Tissue-and developmental-specific expression. Mouse 17HSD7 mRNA is highly expressed in the mouse corpus luteum during the second half of pregnancy. Expression is most abundant around E14.5 when the ovaries are filled with corpora lutea (202) . In the uterus, 17HSD7 is first detected on E5.5 when expression surrounds the implantation site on the antimesometrial side. As gestation progresses, m17HSD7 is expressed in the decidua capsularis on E8 and E9.5, disappearing thereafter from the antimesometrial decidua. From E9 onward, 17HSD7 mRNA expression takes place at the junctional zone of the developing placenta. By E12.5 and E14.5, m17HSD7 is abundantly expressed in the spongiotrophoblasts where expression gradually declines toward parturition. The spatial and temporal expression of m17HSD7 in the uterus suggests that locally produced estradiol plays a role in implantation and/or decidualization. These results indicate that mouse placenta is capable of converting estrone to estradiol in situ, and that the synthesized estradiol may be effective in a paracrine, autocrine, and/or intracrine manner and thus be involved in placentation (202) .
In contrast to rodent enzymes, the physiological significance of human 17HSD7 and its presumed function in reproduction are not well understood. In human, the placenta develops as the major source of estradiol, and 17HSD1 is highly expressed throughout pregnancy for estradiol synthesis in syncytiotrophoblasts. Human 17HSD7 is strongly expressed in the ovaries of nonpregnant women. However, in contrast to rodent enzymes, human 17HSD7 is not detected in the ovaries of pregnant women (208) .
17HSD3
a. Reaction catalyzed. 17HSD3 converts androstenedione, a weak androgen, to testosterone, a potent androgen (Fig. 10) . 17HSD3 prefers NADPH as a cofactor, and its primary activity is reductive.
b. Molecular structure. The human gene HSD17B3, which maps to chromosome 9q22, is 60 kb in length and contains 11 exons. The cDNA encodes a protein of 310 aa with a molecular mass of 34.5 kDa and no apparent membranespanning domain (209) . The cDNA for human 17HSD3 was obtained by expression cloning by Geissler et al. (209) . The cDNA encoding mouse, 17HSD3, was isolated from testis cDNA using the Rapid Amplification cDNA Ends (RACE) technique and primers based on the human sequence (210) . The molecular mass of mouse protein is 33.7 kDa and consists of 305 aa, which is five fewer than those of the human protein.
Four of these aa are missing at the N terminus, and the other is Val 245 of the human sequence. The overall aa identity of mouse protein to human protein is 72.5%, and similarity is 94.8% (210) . The mouse gene, mHsd17b3, maps to chromosome 13 (210) . As mentioned previously, the different 17HSDs, all members of the SDR superfamily, show little homology to each other. 17HSD3 exhibits only 20% identity to 17HSD1 and 17HSD7 (209, 211) .
Structure-function relationships have been deduced from genetic analysis of the 17HSDB3 gene from male pseudohermaphrodite patients with compromised testosterone synthesis. One of the causes of pseudohermaphroditism in male patients was identified as a point mutation in the open reading frame of exon 9 resulting in a loss of catalytic activity of 17HSD3 (209, 212) . Other mutations have been identified that map to exon 3 leading to decreased cofactor (NADPH) binding (209, 212) . The mutations that caused decreased cofactor binding were shown to involve the tyrosine residue at position 80. Site-directed mutational analysis targeted at Tyr 80 demonstrated that this tyrosine is critical for cofactor binding and that substitution with different aa results in alterations in cofactor preference, switching from NADPH to NADH (213) .
c. Tissue-and developmental-specific expression. 17HSD3 is exclusively expressed in testes (209, 211, 214) . Its expression is restricted to the adult Leydig cell population and thus serves as a specific marker for Leydig cell development (215) . O'Shaughnessy et al. (215) examined the mRNA expression of 17HSD3 in the developing mouse testis. They reported that 17HSD3 was expressed in seminiferous tubules until neonatal d 10, with little or no expression observed between d 
D. Regulation of expression of 17HSDs
The expression of 17HSD1 exhibits species-specific differences, which may be due to distinct mechanisms that control cell-and tissue-specific regulation. In ovary, 17HSD1 is primarily induced by FSH acting via the cAMP-dependent protein kinase (PKA) pathway. The extent of PKA-mediated induction of 17HSD1 is modulated by PKC, androgens, estrogens, and various growth factors present in the ovary (200) . Luteinizing agents cause a significant drop in 17HSD1 expression, and thus, 17HSD1 is not expressed in the corpus luteum (200) . In human placental choriocarcinoma cells (JEG-3 cells), retinoic acid, epidermal growth factor, PKA, and PKA activators all increase 17HSD1 expression. The high levels of 17HSD1 that are maintained in syncytiotrophoblasts during pregnancy are thus likely due to the contribution of several factors (195) . Three functional regulatory elements have been described for the human gene, hHSD17B1: a retinoic acid response element; adjacent and competing AP-2, Sp1, and Sp3 elements, which act as transcription enhancers; and a GATA element, which acts as a transcriptional repressor. Deletion of the retinoic acid response element results in loss of response to retinoic acid, which has been shown to enhance 17HSD1 expression in both JEG-3 choriocarcinoma cells and T54D breast cancer cells. Sp1 and Sp3 are widely distributed transcription factors both of which bind to the same GC-rich Sp motif. Sp1 activates a significant number of promoters and has been shown to compete with Sp3 for binding to the shared sequence, thus limiting its activity. AP-2 is activated by several signaling pathways such as PKA and PKC, suggesting that the interaction of Sp1, Sp3, and AP-2 may control the tissue-and cell-specific transcription of the hHSD17B1 gene (195, 216) . Deletion of the GATA binding site in the hHSD17B1 gene results in increased transcription, indicating that GATA factors act as repressors, and GATA-2 and GATA-3 have been shown to bind to this motif in JEG-3 cells (216) . Combinatorial transcriptional regulation of the hHSD17B1 gene by the retinoic acid response element, competing Sp and AP-2 sites, and GATA repressor elements are likely to participate in the expression of the gene and may guide its cell-and tissue-specific expression (200) .
17HSD7 is the major 17HSD expressed in the ovaries of pregnant mice and rats, and the expression pattern parallels estradiol secretion from the corpus luteum. During the luteal phase of the rodent ovarian cycle, estradiol is secreted mainly from the corpus luteum, where 17HSD7, not 17HSD1, is responsible for the final step in estradiol synthesis (200 -202) . If fertilization occurs, the corpora lutea continue to secrete progesterone and estradiol. In the rat, estradiol continues to be produced from ovarian and placental precursors throughout pregnancy as the corpus luteum of pregnancy further matures as a result of prolactin stimulation (217) . In the first half of rat pregnancy, steroidogenesis in the corpus luteum is stimulated by prolactin and LH, and estradiol is synthesized from ovarian androgen precursors. At midpregnancy, LH and prolactin are down-regulated, and the lutealplacental shift takes place, at which time the placenta begins to produce the androgen precursors needed for increased estradiol synthesis by the ovaries.
Regulation of 17HSD3 mRNA expression during development has been examined by Baker et al. (218) using mutant mouse models. They studied the expression of 17HSD3 mRNA in hpg mice, which lack gonadotropins, and Tfm mice, which lack functional androgen receptors. From these studies, it was concluded that during early postnatal development, 17HSD3 expression is independent of gonadotropin stimulation, but after puberty becomes dependent upon testicular descent, gonadotropins, and especially, androgen action (218).
IV. Epilogue: Steroidogenic Enzyme Expression in Nervous System, Heart, and Other Peripheral Sites
Although this review emphasizes the enzymes involved in the biosynthesis of active steroid hormones from cholesterol in gonads, adrenal cells, and placenta, in recent years, evidence has been obtained for the de novo synthesis of some steroid hormones in the nervous system (13, 14) , and more recently, in cardiac tissue (15) (16) (17) . Steroids synthesized in the nervous system are referred to as neurosteroids. The major steroid hormones synthesized in the central and peripheral nervous system are pregnenolone, DHEA, and their sulfates, and reduced metabolites such as 3␣-hydroxy-5␣-pregnane-20-one (13) . Neurosteroids act as paracrine factors within the nervous system, unlike steroid hormones synthesized in gonads and adrenal glands that are carried in the circulation to their target sites where they initiate action. The specific enzymes and their sites of expression in the nervous system are described in the recent review by Mellon and Griffin (14) . All of the studies on the expression of enzymes in the nervous system are based on studies in rodents. Evidence for expression of steroidogenic enzymes in brain, spinal cord, and peripheral nervous system include CYP11A, CYP11B1 and B2, CYP17, CYP19, 3␤HSD, 17HSD, 5␣-reductase and 3␣HSD (14, 219, 220) . To date, there is no evidence for the expression of CYP21 indicating that de novo synthesis of adrenal steroid hormones does not take place in the nervous system (14) . However, this does not rule out the possibility that circulating deoxycortisone or deoxycortisol could function as substrate for neural CYP11B1 or B2. The biological responses of neurosteroids are mediated via either nuclear receptors or neuroreceptors (14) .
Evidence for the expression of steroidogenic enzyme mRNAs in cardiac tissue obtained from human normal and failing hearts as well as cardiac tissue from mice and rats has been reported recently (15, 16) . Kayes-Wandover and White (15) examined the expression of steroidogenic enzyme mRNA in samples from various regions of the adult human heart as well as samples obtained from whole adult and fetal heart. They detected CYP11A, 3␤HSD, CYP21, and CYP11B1 in all samples tested, except in the ventricles, which did not express CYP11B1. CYP11B2 was detected in the aorta and fetal heart, but not in any of the other regions of the adult heart. CYP17 was not detected in any of the cardiac samples. These results suggest that the normal adult heart has the potential for synthesizing corticosterone and deoxycorticosterone, but not cortisol or aldosterone. The relative amount of mRNA detected was approximately 0.1% of the amount expressed in the adult human adrenal. Young et al. (16) examined total RNA isolated from human tissue from failing hearts taken at the time of transplantation surgery or from normal hearts obtained at autopsy. In general, their findings were in agreement with those reported by Kayes-Wandover and White, with the exception that Young et al. detected CYP11B1and CYP11B2 in failing, but not in normal heart samples. These studies by Kayes-Wandover and White (15) and by Young et al. (16) suggest that heart tissue may synthesize corticosteroids for autocrine or paracrine action within the heart, but it is unlikely that physiological levels of aldosterone are synthesized within the heart. Additional studies are needed to establish the relevancy of cardiac expression of steroidogenic enzymes.
In addition to the source of active steroid hormones derived from the circulation, there are numerous tissues that express 3␤HSD, 17HSD, and aromatase, and thus have the capacity to synthesize active steroid hormones from circulating steroid precursors. The expression of these enzymes in target tissues is of particular importance in humans where adrenal glands secrete high amounts of DHEA and DHEA sulfate. These steroids can serve as substrates in peripheral tissues for the conversion to androstenedione by human 3␤HSD I, and subsequently to testosterone by one of the isoforms of 17HSD or to estrone or estradiol by aromatase. The synthesis of active steroid hormones from adrenal secreted precursors allows for the local production of specific steroid hormones within the target cell. This phenomenon has been referred to as "intracrinology" by Labrie and coworkers (221, 222) . Peripheral expression of human 3␤HSD I (223) and mouse 3␤HSD VI (7) occurs in skin. The significance of the expression of 3␤HSD in skin is supported by the finding that in vivo sebum secretion in humans is correlated with in vitro activity of 3␤HSD (224) , and more recently, the demonstration that the expression of 3␤HSD I in sebatocytes, in addition to the expression of 17HSD3, is important to the synthesis of testosterone from adrenal-secreted DHEA (225) . A recent report describes an unexpected requirement for the peripheral expression of 3␤HSD (226) . Differentiation of megacaryocytes into proplatelets is initiated by the megacaryocyte/erythrocyte-specific transcription factor, p45NF-E2. Nagata et al. (226) found that the target of 45NF-E2 is mouse 3␤HSD VI, and furthermore, that the induction of 3␤HSD VI by 45NF-E2 leads to the synthesis of estradiol, which in turn triggers proplatelet formation.
17HSD1 protein has been detected in epithelial cells of human breast tissue and in endometrium. In these tissues, 17HSD1 catalyzes the conversion of estrone derived from the circulation to the more potent estrogen, estradiol (152) . The expression of 17HSD 5 in prostate glands is important for the synthesis of the active androgen, dihydrotestosterone, from adrenal DHEA (187) . The synthesis of dihydrotestosterone in the prostate gland, in addition to 17HSD 5, also requires the expression of human 3␤HSD I as well as 5␣-reductase type 2 (227) .
The peripheral expression of aromatase is critical, especially in men and postmenopausal women. Peripheral expression of aromatase is determined by tissue-specific promoters of the aromatase gene as discussed in the section on CYP19. A major site of peripheral expression of aromatase is in adipose tissues of both men and women (12, 103) . The conversion of C19 androgens to estrogens in adipose tissue increases with age in postmenopausal women and in elderly men (12, 103) . The primary site of expression in adipose tissue is in stromal mesenchymal cells (12) . Although the major source of estrogen for proper epiphyseal closure is derived from peripheral aromatization in adipose tissue, aromatase also is expressed in both osteoblasts and chondrocytes of human males and females (228) . Sasano et al. (228) reported that the amount of expression of aromatase correlated with the degree of osteoporotic changes of lumbar vertebrae.
Brain is another major site of peripheral expression of aromatase. Aromatase is primarily expressed in the hypothalamus and limbic regions of the brain. Early studies on aromatization in the hypothalamus of male and female rats were reported by Naftolin et al. (229) . More recent studies describing the expression of CYP19 in various areas of the brain and retina are reviewed in Simpson et al. (12) and Kamat et al. (103) .
With newly available techniques such as microarray analysis, we predict that many more peripheral sites of expression of steroidogenic enzymes will be found that will lead to the discovery of previously unknown sites of action of steroid hormones.
